Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

TGen to secure emergency FDA approval for 2009 H1N1 flu test

The Phoenix-based non-profit Translational Genomics Research Institute (TGen) announced today that, along with a business collaborator, it will submit a request to the U.S. Food and Drug Administration for emergency use of a new test to diagnose the 2009 H1N1 swine flu virus.

30 Oct 2009

Gen-Probe receives FDA emergency use authorization for its Prodesse ProFlu-ST test

Gen-Probe Incorporated today announced that the US Food and Drug Administration (FDA) has granted an EUA (emergency use authorization) for its test, the Prodesse ProFlu-ST(TM), to be used in CLIA high complexity laboratories for the diagnosis of 2009 H1N1 influenza virus infection, aided by an algorithm that relies on seasonal influenza A/H1 virus and seasonal influenza A/H3 virus results, from a single sample in individuals who are diagnosed with influenza A by currently available FDA-cleared or authorized devices.

29 Oct 2009

Cempra Pharmaceuticals to present CEM-102 data at the Infectious Diseases Society of America meeting

Cempra Pharmaceuticals today announced data presentations of its lead antibiotic candidate, CEM-102 (fusidic acid), at the Infectious Diseases Society of America, 47th Annual Meeting, Oct. 29 to Nov. 1, 2009, in Philadelphia.

29 Oct 2009

Antibiotic effects of pumpkin may help fight yeast infections

The skin of that pumpkin you carve into a Jack-o'-Lantern to scare away ghosts and goblins on Halloween contains a substance that could put a scare into microbes that cause millions of cases of yeast infections in adults and infants each year.

29 Oct 2009

Cempra Pharmaceuticals stages a presentation on CEM-101

Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America, 47th Annual Meeting, October 29 to November 1, 2009, in Philadelphia.

29 Oct 2009

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

Perhaps the most comprehensive, multi-institutional study yet of the sexually transmitted bacteria chlamydia is under way at the University of Maryland, Baltimore (UMB).

29 Oct 2009

NIH awards Excelimmune grant to develop treatment for Clostridium difficile infection

Excelimmune, Inc. (www.excelimmune.com) announced today that the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant to support research aimed at developing new treatments for Clostridium difficile (C. difficile) infection, employing Excelimmune’s expertise in developing novel antibody therapies for human disease.

28 Oct 2009

Pure Protein develops soluble Class II human leukocyte antigens

Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.

28 Oct 2009

New CCS guidelines and position papers for physicians and nurse practitioners

Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.

28 Oct 2009

HHS funds projects to combat health care-associated infections

HHS Secretary Kathleen Sebelius today announced the award of $17 million to fund projects to fight costly and dangerous health care-associated infections, or HAIs.

28 Oct 2009

NIH awards The Tufts CTSI and Tufts University four supplemental grants

The Tufts Clinical and Translational Science Institute (CTSI) and Tufts University today announced they are the recipients of four supplemental grant awards from the National Institutes of Health. These new awards, totaling approximately $1.73 million, are supplements to the original Clinical and Translational Science Award (CTSA) grant, UL1 RR025752 that Tufts University received in 2008 from the National Center for Research Resources.

27 Oct 2009

PolyMedix completes second successful clinical study of PMX-60056

PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders, has completed a second successful clinical study of its anticoagulant reversing agent, PMX-60056.

27 Oct 2009

USAID and USP join to combat substandard and counterfeit medicines

With substandard and counterfeit versions of medicines intended to treat life-threatening diseases such as malaria, HIV/AIDS and tuberculosis posing a growing threat throughout the developing world, the U.S. Agency for International Development (USAID) and the U.S. Pharmacopeial Convention (USP) will expand their joint efforts to combat this menace by launching a new program over the next five years.

27 Oct 2009

Fero Industries to complete acquisition of Pyro Pharmaceuticals by November 30, 2009

Fero Industries, Inc. is pleased to provide certain disclosures relating to the ten pending patent applications of Pyro Pharmaceuticals, Inc. As previously announced, the Company has initiated the process of acquiring Pyro Pharmaceuticals, Inc. through an exchange of Pyro’s capital stock for shares of the Company’s common stock, with Fero remaining as the parent entity and Pyro as a subsidiary. The acquisition of Pyro is expected to close by November 30, 2009.

27 Oct 2009

Researchers explore link between workplace stress and exposure on GI disorders

In two new studies, presented at the American College of Gastroenterology's (ACG) 74th Annual Scientific meeting in San Diego, researchers explored the connection between high stress, high exposure occupations and long-term gastrointestinal disorders.

27 Oct 2009

Study reveals LOAD therapy can eliminate bacterium in patients with gastritis and peptic ulcers

Helicobater pylori, a bacteria implicated in peptic ulcers and gastritis, was eradicated in 95 percent patients who took a 7-day course of combination therapy with levofloxacin, omeprazole, nitazoxanide (Alinia®) and doxycycline (LOAD) compared to eradication in only 80.9 percent of patients on lansoprazole, amoxicillin and clarithromycin (LAC) for seven days.

27 Oct 2009

Anti-Infective Drugs Advisory Committee to review aztreonam for inhalation solution

Gilead Sciences, Inc. today announced that aztreonam for inhalation solution, an investigational product for the treatment of infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF), is scheduled to be reviewed by the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) on December 10, 2009.

27 Oct 2009

Stomach infection on the rise in outpatient settings; symptoms can range from diarrhea to life-threatening inflammation

Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile, (http://www.mayoclinic.org/c-difficile/) is on the rise in outpatient settings.

27 Oct 2009

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

27 Oct 2009

HHS funds $17M for fight against costly and dangerous health care-associated infections

HHS Secretary Kathleen Sebelius today announced the award of $17 million to fund projects to fight costly and dangerous health care-associated infections, or HAIs.

24 Oct 2009

Antibiotic News and Research

Further Reading

TGen to secure emergency FDA approval for 2009 H1N1 flu test

Gen-Probe receives FDA emergency use authorization for its Prodesse ProFlu-ST test

Cempra Pharmaceuticals to present CEM-102 data at the Infectious Diseases Society of America meeting

Antibiotic effects of pumpkin may help fight yeast infections

Cempra Pharmaceuticals stages a presentation on CEM-101

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

NIH awards Excelimmune grant to develop treatment for Clostridium difficile infection

Pure Protein develops soluble Class II human leukocyte antigens

New CCS guidelines and position papers for physicians and nurse practitioners

HHS funds projects to combat health care-associated infections

NIH awards The Tufts CTSI and Tufts University four supplemental grants

PolyMedix completes second successful clinical study of PMX-60056

USAID and USP join to combat substandard and counterfeit medicines

Fero Industries to complete acquisition of Pyro Pharmaceuticals by November 30, 2009

Researchers explore link between workplace stress and exposure on GI disorders

Study reveals LOAD therapy can eliminate bacterium in patients with gastritis and peptic ulcers

Anti-Infective Drugs Advisory Committee to review aztreonam for inhalation solution

Stomach infection on the rise in outpatient settings; symptoms can range from diarrhea to life-threatening inflammation

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

HHS funds $17M for fight against costly and dangerous health care-associated infections

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News